HSP90 and its inhibitors

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1483-1492

  Hao, Huifang ^a   Naomoto, Yoshio ^a   Bao, Xiaohong ^a   Watanabe, Nobuyuki ^a   Sakurama, Kazufumi ^a   Noma, Kazuhiro ^a   Motoki, Takayuki ^a   Tomono, Yasuko ^b   Fukazawa, Takuya ^a   Shirakawa, Yasuhiro ^a   Yamatsuji, Tomoki ^a   Matsuoka, Junji ^a   Takaoka, Munenori ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Shigei Medical Research Institute and Hospital   (Japan)

Author keywords

Chaperone; Heat shock protein 90; Inhibitors

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 4 [4 (1,4 BENZODIOXAN 6 YL) 5 METHYL 1H PYRAZOL 3 YL] 6 ETHYLRESORCINOL; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; BIIB021 PROTEIN; CARBON 11; CELASTROL; DERRUBONE; EPIGALLOCATECHIN GALLATE; GEDUNIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NOVOBIOCIN; NOVOBIOCIN DERIVATIVE; POCHONIN A F; PU24FCL; PURINE 3; RADAMIDE; RADICICOL; RADICICOL OXMIE DERIVATE; SNX 2112; STA9090; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS;

EID: 77951759214     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000787     Document Type: Review

References (142)

1. Csermely P, Schnaider T, Soti C, Prohászka Z and Nardai G: The 90-kDa molecular chaperone family: structure, function and clinical applications. a comprehensive review. Pharmacol Ther 79: 129-168, 1998. (Pubitemid 28380440)
2. Buchner J: Hsp90 & Co. - a holding for folding. Trends Biochem Sci 24: 136-141, 1999.
3. Bagatell R and Whitesell L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3: 1021-1030, 2004. (Pubitemid 39199597)
4. Pratt WB and Toft DO: Regulation of signaling protein function and trafficking by the Hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111-133, 2003. (Pubitemid 36187918)
5. Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M and Garrido C: Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 12: 743-761, 2008.
6. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I and Workman P: Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxy-geldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 19: 4125-4133, 2000.
7. Burrows F, Zhang H and Kamal A: HSP90 activation and cell cycle regulation. Cell Cycle 3: 1530-1536, 2004. (Pubitemid 40521406)
8. Ferrarini M, Heltai S, Zocchi MR and Rugarli C: Unusual expression and locization of heat shock protein in human tumor cells. Int J Cancer 51: 613-619, 1992.
9. Ruden DM, Xiao L, Garfinkel MD and Lu X: Hsp90 and environmental impacts on epigenetic states: a model for the transgenerational effects of diethylstibesterol on uterine development and cancer. Hum Mol Genet 14: R149-R155, 2005. (Pubitemid 40542631)
10. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB and Toft DO: The Hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 275: 3305-3312, 2000. (Pubitemid 30083032)
11. Krishna P and Gloor G: The Hsp90 family of proteins in Arabidopsis thaliana. Cell Stress Chaperon 6: 238-246, 2001.
12. Rebbe NF, Ware J, Bertina RM, Modrich P and Stafford DW: Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene 53: 235-245, 1987. (Pubitemid 17116365)
13. Hoffmann T and Hovemann B: Heat-shockproteins, Hsp84 and Hsp86, of mice and men: two related genes encode formerly identified tumour-specific transplantation antigens. Gene 74: 491-501, 1988. (Pubitemid 19060663)
14. Chen B, Piel WH, Gui L, Bruford E and Monteiro A: The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86: 627-637, 2005. (Pubitemid 41752943)
15. Krone PH and Sass JB: Hsp90a and Hsp90β genes are present in the zebrafish and are differentially regulated on developing embryos. Biochem Biophys Res Commun 204: 746-752, 1994. (Pubitemid 2148355)
16. Stechmann A and Cavalier-Smith T: Evolutionary origins of Hsp90 chaperones and a deep paralogy in their bacterial ancestors. J Eukaryot Microbiol 51: 364-373, 2004. (Pubitemid 38689131)
17. Song HY, Dunbar JD, Zhang YX, Guo D and Donner DB: Identification of a protein with homology to Hsp90 that binds the type 1 tumor necrosis factor receptor. J Bio Chem 270: 3574-3581, 1995.
18. Grammatikakis N, Vultur A, Ramana CV, Siganou A, Schweinfest CW, Watson DK and Raptis L: The role of HSP90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Bio Chem 277: 8312-8320, 2002. (Pubitemid 34968291)
19. Shiau AK, Harris SF, Southworth DR and Agard DA: Structural analysis of E. coli Hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 127: 329-340, 2006.
20. Huai Q, Wang H, Liu Y, Kim HY, Toft D and Ke H: Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure 13: 579-590, 2005.
21. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90: 65-75, 1997. (Pubitemid 28009419)
22. Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, Prodromou C and Pearl LH: Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440: 1013-1017, 2006.
23. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU and Pavletich NP: Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89: 239-250, 1997. (Pubitemid 27199896)
24. Richter K, Soroka J, Skalniak L, Leskovar A, Hessling M, Reinstein J and Buchner J: Conserved conformational changes in the ATPase cycle of human Hsp 90. J Biol Chem 283: 17757-17765, 2008.
25. Garnier C, Lafitte D, Tsvetkov PO, Barbier P, Leclerc-Devin J, Millot JM, Briand C, Makarov AA, Catelli MG and Peyrot V: Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem 277: 12208-12214, 2002. (Pubitemid 34952787)
26. Minami Y, Kawasaki H, Suzuki K and Yahara I: The calmodulin-binding domain of the mouse 90-kDa heat shock protein. J Biol Chem 268: 9604-9610, 1993. (Pubitemid 23146018)
27. Minami Y, Kimura Y, Kawasaki H, Suzuki K and Yahara I: The carboxy-terminal region of mammalian HSP90 is required for its dimerization and function in vivo. Mol Cell Biol 14: 1459-1464, 1994. (Pubitemid 24036596)
28. Chen S, Sullivan WP, Toft DO and Smith DF: Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperones 3: 118-129, 1998. (Pubitemid 28327424)
29. Prodromou C, Siligardi G, O'Brien R, Woolfson DN, Regan L, Panaretou B, Ladbury JE, Piper PW and Peral LH: Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J 18: 754-762, 1999. (Pubitemid 29057260)
30. Scheufler C, Brinker A, Bourenkov G, Pegoraro S, Moroder L, Bartunik H, Harl FU and Moarefi I: Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 101: 199-210, 2000. (Pubitemid 32004747)
31. Hawl P, Siepmann M, Harst A, Siderius M, Reusch HP and Obermann WM: The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol Cell Biol 26: 8385-8395, 2006. (Pubitemid 44748572)
32. Harst A, Lin H and Obermann WM: Aha1 competes with Hop, p50 and p23 for binding to the molecular chaperone Hsp90 and contributes to kinase and hormone receptor activation. Biochem J 387: 789-796, 2005. (Pubitemid 40685714)
33. Lotz GP, Lin H, Harst A and Obermann WM: Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 278: 17228-17235, 2003. (Pubitemid 36799604)
34. Meyer P, Prodromou C, Hu B, Vaughan C, Roe SM, Panaretou B, Piper PW and Pearl LH: Structural and functional analysis of the middle segment of Hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 11: 647-658, 2003. (Pubitemid 36385120)
35. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, Millson SH, Clarke PA, Naaby-Hansen S, Stein R, Cramer R, Mollapour M, Workman P, Piper PW, Pearl LH and Prodromou C: Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone aha1. Mol Cell 10: 1307-1318, 2002. (Pubitemid 36050873)
36. Prodromou C, Roe SM, Piper PW and Pearl LH: A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nature Struct Biol 4: 477-482, 1997. (Pubitemid 27263601)
37. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM and Toft DO: The amino-terminal domain of heat shock protein90 (Hsp90) that binds Geldanamycin is an ATP/ADP switch domain that regulates Hsp90 conformation. J Biol Chem 272: 23843-23850, 1997. (Pubitemid 27410964)
38. Obermann WM, Sondermann H, Russo AA, Pavletich NP and Hartl FU: In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143: 901-910, 1998.
39. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH: ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 17: 4829-4836, 1998. (Pubitemid 28377183)
40. Chadli A, Bouhouche I, Sullivan W, Stensgard B, McMahon N, Catelli MG and Toft DO: Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proc Natl Acad Sci USA 97: 12524-12529, 2000.
41. Young JC, Moarefi I and Hartl FU: Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154: 267-273, 2001. (Pubitemid 34286138)
42. Söti C, Rácz A and Csermely P: A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 277: 7066-7075, 2002. (Pubitemid 34953095)
43. Richter K, Moser S, Hagn F, Friedrich R, Hainzl O, Heller M, Schlee S, Kessler H, Reinstein J and Buchner J: Intrinsic inhibition of the Hsp90 ATPase activity. J Biol Chem 281: 11301-11311, 2006. (Pubitemid 43855555)
44. Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM: Inhibition of heat shock protein HSP90-pp6Ov-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91: 8324-8328, 1994. (Pubitemid 24273656)
45. Supko JG, Hickman RL, Grever MR and Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36: 305-315, 1995.
46. Schnur RC, Corman ML, Gallaschun RJ, et al: Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38: 3806-3812, 1995.
47. Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV and Myles DC: Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem 12: 5317-5329, 2004. (Pubitemid 39243952)
48. Schulte TW and Neckers LM: Thebenzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279, 1998. (Pubitemid 28393843)
49. Solit DB and Chiosis G: Development and application of Hsp90 inhibitors. Drug Discovery Today 13: 38-43, 2008.
50. Hostein I, Robertson D, Di Stefano F, Workman P and Clarke PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethox- ygeldanamycin results in cytostasis and apoptosis. Cancer Res 61: 4003-4009, 2001. (Pubitemid 32720963)
51. Münster PN, Basso A, Solit D, Norton L and Rosen N: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E.A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxy- geldanamycin: sequence and tumor biology matters. Clin Cancer Res 7: 2155-2158, 2001.
52. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J and Motzer RJ: A phase II trial of 17-(allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24: 543-546, 2006. (Pubitemid 44273031)
53. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM and Eiseman JL: Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47: 291-302, 2001. (Pubitemid 32640768)
54. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D and Ross D: Formation of 17-allylamino-demethoxy-geldanamycin (17-AAG) hydroquinone by NAD(P)H: quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65: 10006-10015, 2005. (Pubitemid 41541482)
55. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, GaoY, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J and Palombella VJ: Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 49: 4606-4615, 2006. (Pubitemid 44162687)
56. Sausville EA, Tomaszewski JE and Ivy P: Clinical development of 17-allylamino,17-demethoxy-geldanamycin. Curr Cancer Drug Targets 3: 377-383, 2003.
57. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N and Chapman PB: PhaseII trial of 17-allylamino-17-demethoxy geldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302-8307, 2008.
58. Chiosis G, Caldas Lopes E and Solit D: Heat shock protein-90 inhibitors a chronice from geldanamycin to today's agents. Curr Opin Investig Drugs 7: 534-541, 2006. (Pubitemid 43891032)
59. Smith V, Sausville EA, Camalier RF, Fiebig HH and Burger AM: Comparison of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 56: 126-137, 2005. (Pubitemid 40884268)
60. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH and Sausville EA: In vivo antitumor efficacy of 17-DMAG (17- dimethylaminoethylamino-17-demethoxygeldanamycinhydrochloride) a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 56: 115-125, 2005.
61. Hwang K, Scripture CD, Gutierrez M, Kummar S, Figg WD and Sparreboom A: Determination of the heat shock protein 90 inhibitor 17-dimethyl aminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 830: 35-40, 2006. (Pubitemid 41831385)
62. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM and Eiseman JL: Pharmaco kinetics, tissue distribution and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49: 7-19, 2002.
63. Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, Brown AP, Levine BS, Covey JM, Egorin MJ, Eiseman JL, Holleran JL, Sausville EA and Tomaszewski JE: Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56: 637-647, 2005.
64. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM and Eiseman JL: Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58: 2385-2396, 1998.
65. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM and Egorin MJ: Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-{[(2-dimethylamino)ethyl]amino} geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55: 21-32, 2005. (Pubitemid 40064492)
66. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J and Tong JK: Development of 17-allylamino-17-demethoxygel-danamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103: 17408-17413, 2006. (Pubitemid 44788982)
67. Siegel D, Jagannath S, Mazumder A, Vesole D, Borrello I, Sydor JR, Wright J, Patterson J, Normant E, Adams J, Anderson KC, Grayzel DS and Richardson PG: Update on phase I clinical trial of IPI-504, a novel, water soluble Hsp90 inhibitor, in patients with relapsed/refractory multiple myeloma. (ASH Annual Meeting Abstracts) Blood 108: abs. 3579, 2006.
68. Tian ZQ, Wang Z, MacMillan KS, Zhou Y, Carreras CW, Mueller T, Myles DC and Liu Y: Potent cytotoxic C-11 modified geldanamycin analogues. J Med Chem 52: 3265-3273, 2009.
69. Ki SW, Ishigami K, Kitahara T, Kasahara K, Yoshida M and Horinouchi S: Radicicol binds and inhibits mammalian ATP citrate lyase. J Biol Chem 275: 39231-39236, 2000. (Pubitemid 32058941)
70. Kwon HJ, Yoshida M, Abe K, Horinouchi S and Beppu T: Radicicol, an agent inducing the reversal of transformed phenotypes of src-transformed fibroblasts. Biosc Biotech Biochem 56: 538-539, 1992.
71. Kwon HJ, Yoshida M, Fukui Y, Horinouchi S and Beppu T: Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res 52: 6926-6930, 1992. (Pubitemid 23006300)
72. Kwon HJ, Yoshida M, Muroya K, Hattori S, Nishida E, Fukui Y, Beppu T and Horinouchi S: Morphology of ras-transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras-GTP complex. J Biochem 118: 221-228, 1995.
73. Chanmugam P, Feng L, Liou S, Lee JH, Jang BC, Boudreau M, Yu G, Kwon HJ, Beppu T, Yoshida M, Xia Y, Wilson CB and Hwang D: Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis. J Biol Chem 270: 5418-5426, 1995.
74. Oikawa T, Ito H, Ashino H, Toi M, Tominaga T, Morita I and Murota S: Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis. Eur J Pharmacol 241: 221-227, 1993. (Pubitemid 23272883)
75. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH: Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42: 260-266, 1999. (Pubitemid 29069861)
76. Soga S, Kozawa T, Narumi H, Akinaga S, Irie K, Matsumoto K, Sharma SV, Nakano H, Mizukami T and Hara M: Radicicol leads to selective depletion of raf kinase and disrupts K-ras-activated aberrant signaling pathway. J Biol Chem 273: 822-828, 1998. (Pubitemid 28049172)
77. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D and Neckers LM: The antibiotic radicicol to the N-terminal domain of Hsp90 and shares important biological activities with geldanamycin. Cell Stress Chaperones 3: 100-108, 1998. (Pubitemid 28327422)
78. Sharma SV, Agatsuma T and Nakano H: Targeting of the protein chaperone, Hsp90, by the transformation suppressing agent, radicicol. Oncogene 16: 2639-2645, 1998. (Pubitemid 28264041)
79. Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T and Akinaga S: KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 59: 2931-2938, 1999. (Pubitemid 29283134)
80. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T and Akinaga S: Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96: 2284-2291, 2000.
81. Kwon HJ, Yoshida M, Nagaoka R, Obinata T, Beppu T and Horinouchi S: Suppression of morphological transformation by radicicol is accompanied by enhanced gelsolin expression. Oncogene 15: 2625-2631, 1997. (Pubitemid 27507254)
82. Agatsuma T, Ogawa H, Akasaka K, Asai A, Yamashita Y, Mizukami T, Akinaga S and Saitoh Y: Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg Med Chem 10: 3445-3454, 2002.
83. Hellwig V, Mayer-Bartschmid A, Muelle H, Greif G, Kleymann G, Zitzmann W, Tichy HV and Stadler M: Pochonins A-F, new antiviral and antiparasitic resorcylic acid lactones from Pochonia chlamydosporia var. catenulata. J Nat Prod 66: 829-837, 2003.
84. Barluenga S, Lopez P, Moulin E and Winssinger N: Modular asymmetric synthesis of pochonin C. Angew Chem Int Ed Engl 43: 3467-3470, 2004.
85. Clevenger RC and Blagg BS: Design, synthesis and evaluation of a radicicol and geldanamycin chimera radamide. Org Lett 6: 4459-4462, 2004.
86. Wang M, Shen G and Blagg BS: Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorg Med Chem Lett 16: 2459-12262, 2006.
87. Hadden MK and Blagg BS: Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. J Org Chem 74: 4697-4704, 2009.
88. Hooper DC, Wolfson JS, McHugh GL, Winters MB and Swartz MN: Effects of novobiocin, coumermycin A1, clorobiocin and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother 22: 662-671, 1982.
89. Tanitame A, Oyamada Y, Ofuji K, Fujimoto M, Suzuki K, Ueda T, Terauchi H, Kawasaki M, Nagai K, Wachi M and Yamagishi J: Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring. Bioorg Med Chem 12: 5515-5524, 2004. (Pubitemid 39304051)
90. Laurin P, Ferroud D, Schio L, Klich M, Dupuis-Hamelin C, Mauvais P, Lassaigne P, Bonnefoy A and Musicki B: Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B. Bioorg Med Chem Lett 9: 2875-2880, 1999. (Pubitemid 29481181)
91. Ali JA, Jackson AP, Howells AJ and Maxwell A: The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydro-lyzes ATP and binds coumarin drugs. Biochemistry 32: 2717-2724, 1993.
92. Bergerat A, De Massy B, Gadelle D, Varoutas PC, Nicolas A and Forterre P: An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature 386: 414-417, 1997. (Pubitemid 27154484)
93. Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H, Lee YS, Simen BB, Argon Y, Felts S, Toft DO, Neckers LM and Sharma SV: Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Mol Endocrinol 13: 1435-1448, 1999. (Pubitemid 30650587)
94. Marcu MG, Schulte TW and Neckers L: Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 92: 242-248, 2000.
95. Allan RK, Mok D, Ward BK and Ratajczak T: Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90. J Biol Chem 281: 7161-7171, 2006.
96. Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B and Blagg BS: Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc 127: 12778-12779, 2005. (Pubitemid 41339147)
97. Burlison JA, Neckers L, Smith AB, Maxwell A and Blagg BS: Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. J Am Chem Soc 128: 15529-15536, 2006. (Pubitemid 44876029)
98. Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers LM: The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275: 37181-37186, 2000. (Pubitemid 32002137)
99. Burlison JA and Blagg BS: Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Org Lett 8: 4855-4858, 2006.
100. Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J and Blagg BS: Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem 73: 2130-2137, 2008. (Pubitemid 351497740)
101. Huang YT and Blagg BS: A library of noviosylated coumarin analogues. J Org Chem 72: 3609-3613, 2007.
102. Le Bras G, Radanyi C, Peyrat JF, Brion JD, Alami M, Marsaud V, Stella B and Renoir JM: New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J Med Chem 50: 6189-6200, 2007.
103. Radanyi C, Le Bras G, Messaoudi S, Bouclier C, Peyrat JF, Brion JD, Marsaud V, Renoir JM and Alami M: Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (Hsp90). Bioorg Med Chem Lett 18: 2495-2498, 2008.
104. Fujiki H: Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 125: 589-597, 1999. (Pubitemid 29502339)
105. Palermo CM, Westlake CA and Gasiewicz TA: Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90-kDa heat shock protein. Biochemistry 44: 5041-5052, 2005.
106. Li Y, Zhang T, Jiang Y, Lee HF, Schwartz SJ and Sun D: (-)- Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol Pharm 6: 1152-1159, 2009.
107. Khalid SA, Duddeck H and Gonzalez-Sierra M: Isolation and characterization of an antimalarial agent of the neem tree Azadirachta indica. J Nat Prod 52: 922-926, 1989.
108. Nathan SS, Kalaivani K, Chang PG and Murugan K: Effect of neem limonoids on lactate dehydrogenase (LDH) of the rice leaf holder, C naphalocrocismedinalis (Guenee) (Insecta: Lepidoptera: Pyralidae). Chemosphere 62: 1388-1393, 2006.
109. Uddin SJ, Nahar L, Shilpi JA, Shoeb M, Borkowski T, Gibbons S, Middleton M, Byres M and Sarker SD: Gedunin, a limonoid from Xylocarpus granatum, inhibits the growth of CaCo-2 colon cancer cell line in vitro. Phytother Res 21: 757-761, 2007.
110. Calixto JB, Campos MM, Otuki MF and Santos AR: Anti-inflammatory compounds of plant origin. Part II: modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 70: 93-103, 2004.
111. Guo JL, Yuan SX, Wang XC, Xu SX and Li DD: Tripterygium wilfordii Hook f in rheumatoid arthritis and ankylosing spondylitis. Preliminary report. Chin Med J (Engl) 94: 405-412, 1981.
112. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y and Sakato N: Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 67: 1883-1887, 2003.
113. Yang H, Chen D, Cui QC, Yuan X and Dou QP: Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine' is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765, 2006.
114. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES and Golub TR: The connectivity map: using gene expression signatures to connect small molecules, genes and disease. Science 313: 1929-1935, 2006.
115. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G and Golub TR: Gene expression signature based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330, 2006. (Pubitemid 44512193)
116. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG and Sun D: A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37complex against pancreatic cancer cells. Mol Cancer Ther 7: 162-170, 2008.
117. Sreeramulu S, Gande SL, Göbel M and Schwalbe H: Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 48: 5853-5855, 2009.
118. Hadden MK, Galam L, Gestwicki JE, Matts RL and Blagg BS: Derrubone, an inhibitor of the Hsp90 protein folding machinery. J Nat Prod 70: 2014-2018, 2007.
119. Hastings JM, Hadden MK and Blagg BS: Synthesis and evaluation of derrubone and select analogues. J Org Chem 73: 369-373, 2008.
120. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L and Rosen N: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 8: 289-299, 2001.
121. Chiosis G, Lucas B, Shtil A, Huezo H and Rosen N: Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 10: 3555-3564, 2002.
122. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P and Chiosis G: Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 11: 787-797, 2004.
123. Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P and Chiosis G: Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 48: 2892-2905, 2005.
124. Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC, Kamal A, Lough RE, Lundgren K, Burrows FJ, Timony GA, Boehm MF and Kasibhatla SR: Orally active purine-based inhibitors of Hsp90. J Med Chem 49: 817-828, 2006.
125. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT and Chiosis G: Identification of potent water soluble purine scaffold inhibitors of the heat shock protein 90. J Med Chem 49: 381-390, 2006.
126. Taldone T, Gozman A, Maharaj R and Chiosis G: Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8: 370-374, 2008.
127. Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF and Burrows FJ: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 8: 921-929, 2009.
128. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F and Shores CG: BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 126: 1216-1225, 2010.
129. Zhang H, Neely L, Lundgren K, Yang YC, Lough R, Timple N and Burrows F: BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer 126: 1226-1234, 2010.
130. Elfiky A, Saif MW, Beeram M, Brien SO, Lammanna N, Castro JE, Woodworth J, Perea R, Storgard C and von Hoff DD: BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. J Clin Oncol 26: abs. 2503, 2008.
131. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P and Aherne W: High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 327: 176-183, 2004. (Pubitemid 38402186)
132. Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, Aherne GW, McDonald E and Workman P: The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 15: 3338-3343, 2005.
133. Kreusch A, Han S, Brinker A, Zhou V, Choi HS, He Y, Lesley SA, Caldwell J and Gu XJ: Crystal structures of human HSP90 alpha-complexed with dihydroxyphenylpyrazoles. Bioorg Med Chem Lett 15: 1475-1478, 2005.
134. Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KM, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E and Workman P: In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 67: 2206-2216, 2007.
135. Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley SD, Webb P, Workman P, Wright L and Drysdale MJ: Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48: 4212-4215, 2005.
136. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P and Wright L: 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196-218, 2008.
137. Hammond LA, Denis L, Salman U, Jerabek P, Thomas CR Jr and Kuhn JG: Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs 21: 309-340, 2003.
138. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N and Solit DB: SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase dependent cancers. Clin Cancer Res 14: 240-248, 2008.
139. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S and Anderson KC: SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-855, 2009.
140. Jin L, Xiao CL, Lu CH, Xia M, Xing GW, Xiong S, Liu QY, Liu H, Li YC, Ge F, Wang QD, He QY and Wang YF: Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS Lett 583: 1859-1866, 2009.
141. Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J and London C: The novel HSP90 inhibitor STA-9090 exhibits activity against kit-dependent and -independent malignant mast cell tumors. Exp Hematol 36: 1266-1277, 2008.
142. McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J and London CA: The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 125: 2792-2801, 2009.